

# European Reimbursement and market access in 2025: Beyond JCA

While we are certainly all on lookout for the first EU Joint Clinical Assessments (JCA), there are quite a few other access, financing, pricing and reimbursement news and changes to watch as 2025 starts.

By no means exhaustive, some of my topics to watch:



## FRANCE

- 2024 ended without a PLFSS for 2025 but with a vote of non-confidence. Whether the new Government will base its new PLFSS on the last provisions adopted or if it will start from scratch is still unknown.
- More focus on health economic evidence: the HAS creates a new division: The service de l'évaluation économique (S2E)



## GERMANY

- Potential for confidential medicine prices
- Potential for more favourable price rules if at least 5% of study participants are from a German site
- The hospital funding reform starting to be operationalised
- Elections in March 2025



## SPAIN

- New HTA processes for medicines and medical devices
- New pricing regulation for medicines under discussion



## UK

Relaunch of the new ILAP innovation approval / access scheme in March 2025



Henrike Granzow

✉ [granzow@apersy.com](mailto:granzow@apersy.com)

Apersy

Value | Market Access | Commercialisation



[apersy.com](https://apersy.com)